The Disposable Blood Bags Market, estimated at USD 283.6 Mn in 2025, is expected to exhibit a CAGR of 5.47% and reach USD 411.7 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Disposable blood bags are used in sold in government hospitals and national blood banks through government contracts and procurements through the bidding process. Privately funded hospitals, clinics, and blood banks also demand disposable blood bags. NGOs also use disposable plastic blood collection bags during blood donation campaigns. The global disposable blood bags market for cancer supportive care was estimated to account for US$ 411.7 Mn in terms of value by the end of 2032.
Global Disposable Blood Bags Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic had a drastic impact on the global disposable blood bags market. For instance, according to the 2025 data, during the post-lockdown pandemic year blood donation was majorly by repeat donors (83%) from the in-house site (82.5%). Furthermore, the proportion of outdoor donation, deferral, blood collection, demand, and issue demonstrated a significant drop of 50%, 32.6%, 33%, 31.8%, and 32.3%, respectively, in comparison to the non-pandemic years.
Global Disposable Blood Bags Market: Key Developments
- In April 2025, a new blood bank center was inaugurated by the American Oncology Institute at Babina Speciality Hospital, Imphal East, India where private hospitals, including bedridden patients at homecare, can avail of the service.
- In April 2025, is a medical technology company. The products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Terumo Blood and Cell Technologies received a US$ 10.6 million contract to continue its work on freeze-dried plasma (FDP). The contract is with (MTEC), the Medical Technology Enterprise Consortium, a biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command sponsored by the Defense Health Agency (DHA) and managed by the Naval Medical Research Center (NMRC) to drive healthcare advances on the battlefield.